BMBernardo Meza-Torres

Bernardo Meza-Torres

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bernardo Meza-Torres has a total of 254 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metabolic dysfunction-associated steatotic liver disease in primary care: an international Delphi consensus

    by Gong Feng, Shouping Gong, Frank Tacke, Luca Valenti, Mark Muthiah, Koki Kato, Zhaoxiang Yu, Giovanni Targher, Christopher D Byrne, Mohamed Farouk Allam, et al.

  • Open Access

    Pneumococcal Vaccination Uptake in People With Immunosuppressed Conditions Using Real-World Primary Care Data Across England: Protocol for a Retrospective Descriptive Study

    by Bernardo Meza, Gavin Jamie, Jose Ordóñez-Mena, Rachel Byford, Timea Suli, Michael Bride, Benoît Corriveau, Michael Feher, Martin Whyte, Mark Joy, et al.

    Background: The introduction of pneumococcal vaccination programs in the United Kingdom has led to substantial reduction in the burden of pneumococcal disease in the general population, decreasing the incidence of invasive pneumococcal disease and preventing associated mortality. Current UK guidelines recommend pneumococcal vaccination for adults aged ≥65 years, as well as for individuals aged ≥2 years with underlying medical conditions that place them at increased risk of severe pneumococcal disease. This includes adults with immunosuppression. To date, there are few data in the United Kingdom of pneumococcal vaccine coverage in specific high-risk groups, such as those with immunocompromised conditions. Objective: We aim to evaluate the yearly uptake of pneumococcal vaccine in adults who are included in national recommendations as people with immunosuppressive conditions, stratified by etiology of immunosuppression. Methods: This will be a retrospective cohort study with data from the Oxford-Royal College of General Practitioners Research and Surveillance Centre network, which is nationally representative of the English population. The population under study includes adults registered in the Research and Surveillance Centre database with immunosuppression, including those with bone marrow compromise, with solid organ transplant, receiving oncological treatment, using immunosuppressive drugs, or with primary or acquired immunodeficiencies. The exposure is the underlying medical condition leading to an immunosuppression category. The primary outcome will be pneumococcal vaccination, defined as one dose of the 23-valent pneumococcal polysaccharide vaccine (PPV23). Results: The study was funded in May 2025, and data extraction was performed from December 2025 to February 2026. Analysis was started in March 2026, with final results expected to be submited for publication in 2026. We will report pneumococcal vaccine uptake disaggregated for the high-risk group of people with immunosuppressive conditions, which has not been previously reported. We will also report on the socioeconomic gradient for vaccine uptake (through the use of the Index of Multiple Deprivation score and region) and report on the differences among ethnic groups. Conclusions: We will inform on the granularity of routine primary care data to include disaggregated reports of vaccine uptake in the immunosuppressed population in routine surveillance in the United Kingdom. This will aim to address the gap on pneumococcal vaccination coverage in people with immunosuppressive conditions, helping to identify potential unwarranted variations in vaccine adoption.

  • Open Access

    Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice ( CombiKid Study)

    by William Hinton, Mark Joy, Anna K. Forbes, Martin B. Whyte, José M. Ordóñez‐Mena, Xuejuan Fan, Filipa Ferreira, Bernardo Meza‐Torres, Neil Munro, Simon de Lusignan, et al.

    Aims: Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods: Retrospective cohort study with a prevalent new‐user design using pseudonymised data from the Oxford‐Royal College of General Practitioners Research and Surveillance Centre primary care sentinel network. We extracted data for two cohorts prescribed SGLT2is and/or GLP‐1 RAs between January 2013 and December 2021. We 1:1 propensity score matched SGLT2i plus GLP‐1 RA combination users with monotherapy (SGLT2i or GLP‐1RA) users. Multivariable linear regression analyses estimated adjusted mean differences in absolute change in estimated glomerular filtration rate (eGFR) (baseline to 1‐ and 2‐years follow‐up) between combination and monotherapy. Results: Across the matched combination and SGLT2i monotherapy groups ( N = 14 774), mean decline in eGFR, baseline to 1‐year, was −4.5 mL/min/1.73 m 2 and 2‐years, −5.0 mL/min/1.73 m 2 , with no difference when comparing combination and SGLT2i monotherapy. Across the matched combination and GLP‐1 RA monotherapy groups ( N = 14 154), mean decline in eGFR, baseline to 1‐year, was −5.4 mL/min/1.73 m 2 and 2‐years, −6.1 mL/min/1.73 m 2 , but combination therapy was associated with a smaller eGFR reduction compared with GLP‐1 RA monotherapy (difference in eGFR at 1‐year: [mean, 95% confidence interval, CI] 2.2, 1.7 to 2.8, p < 0.001; and at 2‐years: 2.1, 1.4–2.7, p < 0.001). Conclusions: In real‐world clinical practice, the combination of SGLT2i and GLP‐1 RA may be more effective for preserving kidney function than GLP‐1 RA monotherapy. This effect was not seen with combination versus SGLT2i monotherapy.

  • Open Access

    Prediction of COVID-19 hospitalisation, ICU admission or death following ChAdOx1 vaccination using artificial intelligence: A clinical predictive model from the English RAVEN study

    by Anshul Thakur, Bernardo Meza-Torres, Xuejuan Fan, Rachel Byford, Mark Joy, Wilhelmine Meeraus, Sudhir Venkatesan, Sylvia Taylor, Simon de Lusignan, David A. Clifton

    Objectives: This study identifies predictors of severe COVID-19 following completion of two-dose primary series of the AZD1222 COVID-19 vaccine, employing eXtreme Gradient Boosting (XGBoost) and Shapely additive explanations (SHAP), as an explainable artificial intelligence (AI) approach. Method: A retrospective cohort study using linked primary care data from the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub (ORCHID), including computerised medical records of over 19 million people in England, for the period from 8th December 2020–31st December 2021, as part of the Real-world effectiveness of the AZD1222 COVID-19 vaccine in England (RAVEN) study. We evaluated a two-dose primary series of the AZD1222 vaccine on COVID-19 related hospitalisation, ICU admission or death. Results: A total of 4,515,280 individuals with a two-dose primary series of AZD1222 vaccine were analysed, where 7,171 individuals had a record of severe COVID-19. Variables with the greatest predictive weight for COVID-19 mortality in vaccinated individuals were age ≥ 85 years, high Cambridge Multi-Morbidity Score, and chronic heart, respiratory and kidney diseases; variables predicting COVID-19 hospitalisation following completed primary series included high CMMS, obesity, and being offered early COVID-19 vaccination in the national vaccine campaign (e.g., vaccinated during the first quarter of 2021); predictors of COVID-19 ICU admission included obesity, female sex, being offered early COVID-19 vaccination in the national vaccine campaign, chronic kidney disease and diabetes. Across models, age ≥ 85 years was highly predictive of mortality and moderately predictive of hospitalisation. However, for ICU admission it was reported as not predictive. Conclusion: Obesity, chronic heart, respiratory and kidney diseases were the main predictors across models, which is comparable to the scientific literature, validating the explainable AI approach. XGBoost can accurately predict severe outcomes in fully vaccinated individuals. Predictive models built on real-world primary care data can help to timely identify individuals to be prioritised for vaccination booster.

  • Open Access

    Pneumococcal vaccination uptake in people with immunosuppressed conditions using real-world primary care data across England: Protocol for a retrospective descriptive study (Preprint)

    by Bernardo Meza, Gavin Jamie, Jose Ordóñez-Mena, Rachel Byford, Timea Suli, Michael Bride, Benoît Corriveau, Michael Feher, Martin Whyte, Mark Joy, et al.

    BACKGROUND The introduction of pneumococcal vaccination programmes in the UK has led to substantial reduction in the burden of pneumococcal disease in the general population, decreasing the incidence of invasive pneumococcal disease (IPD) and preventing associated mortality. OBJECTIVE We aim to evaluate the yearly uptake of pneumococcal vaccine in adults who are included in national recommendations as people with immunosuppressive conditions, stratified by aetiology of immunosuppression. METHODS This will be a retrospective cohort study with data from the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network, which is nationally representative of the English population. The population are adults registered in the RSC database with immunosuppression, including those with bone marrow compromise, solid organ transplant, receiving oncological treatment, using immunosuppressive drugs, or with primary or acquired immunodeficiencies. The exposure is the underlying medical condition leading to an immunosuppression category. The primary outcome will be pneumococcal vaccination, defined as one dose of PPV23. Vaccination rates will be calculated using the number of vaccinated people in high-risk groups as the numerator and estimates of the total high-risk population in the RSC dataset as the denominator. We will compare amongst vaccinated and unvaccinated people, and across immunosuppressive aetiologies using descriptive statistics, with pairwise comparisons using standardized mean differences. RESULTS We will report pneumococcal vaccine uptake disaggregated for the high-risk group of people with immunosuppressive conditions, which have not been previously reported. We will report on the socioeconomic gradient for vaccine uptake, through the use of the index of multiple deprivation score and region; report on the differences amongst ethnic groups; and report on vaccination uptake during the COVID-19 pandemic period. We will curate an ontology for immunosuppressive conditions, contributing to CMR research following the open science frameworks for reproducible research. CONCLUSIONS We will inform on the granularity of routine primary care data to include disaggregated reports of vaccine uptake in the immunosuppressed population in routine surveillance in the UK. This will aim to address the gap on pneumococcal vaccination coverage in people with immunosuppressive conditions, helping to identify potential unwarranted variations in vaccine adoption.

  • Open Access

    Exploring the implementation and integration of structured medication reviews in primary care: A qualitative evaluation using normalization process theory

    by Claire Reidy, Anna Seeley, Katherine Tucker, Paul A Bateman, Christopher E Clark, Andrew Clegg, Gary A Ford, Seema Gadhia, William Hinton, F D Richard Hobbs, et al.

    Background: Structured Medication Reviews (SMRs) were introduced into primary care in England for patients living with multiple long-term conditions (MLTCs), polypharmacy, increased frailty, in care homes or at risk of medicines-related harm. SMRs aim to optimise the therapeutic potential of medication and reduce medicine-related harms through holistic reviews. Aim: To explore the day-to-day work being undertaken with, and by, clinical pharmacists to implement, embed and integrate SMRs into practice, and consider how to optimise SMRs. Design and setting: Qualitative one-to-one interviews with clinical pharmacists undertaking SMRs and SMR service leaders/managers (SMR leads) in England between February 2023 and November 2024. Method: Participants were recruited as part of a wider evaluation of the roll-out of SMRs in England. Interview topic guides and qualitative data analysis were informed by Normalization Process Theory (NPT). Results: Eighteen clinical pharmacists and five SMR leads participated. Participants reported often having to explain the purpose of SMRs and clinical pharmacists’ roles to patients, partly due to patients not being informed about SMRs. Participants valued SMRs and expressed that trust-building and tailored consultations were important for optimising medications. Integration varied due to high workload, inconsistent leadership support, inadequate administrative/pharmacist technician resource and lack of training. However, participants described SMRs as valuable for identifying and addressing unmet needs and supporting holistic, person-centred care across MLTC pathways. Conclusion: The findings demonstrate the need for improved information on SMRs for patients and primary care teams, adequate and appropriate resource allocation, and enhanced support for consultation skills training to optimise medicines use. How this fits in: - SMRs were formally introduced to primary care in 2020 to address the challenges of managing polypharmacy in an ageing population with increasing patient complexity and MLTCs. - SMRs were introduced alongside the expansion of clinical pharmacist roles in General Practice as a comprehensive, person-centred review of all a patient’s medicines. - This qualitative evaluation examines the day-to-day work of implementing and embedding SMRs, highlighting challenges to implementation and integration. - Our findings reveal challenges to the sustainability of SMRs and identify opportunities for optimisation, including addressing pharmacists’ training needs and resource allocation for administrative and pharmacy technician support.

  • Open Access

    Hepatitis A vaccination coverage in adults with chronic liver disease in primary care in England: a retrospective cohort study

    by Bernardo Meza-Torres, Gavin Jamie, Rashmi Wimalaratna, Robert Williams, Rachel Byford, Anna Forbes, William Elson, William Hinton, Jose M Ordóñez-Mena, Marinos Pericleous, et al.


  • Open Access

    Phenotype Execution and Modelling Architecture (PhEMA) to support disease surveillance and real-world evidence studies: English sentinel network evaluation

    by Gavin Jamie, William Elson, Simon de Lusignan, Debasish Kar, Rashmi Wimalaratna, Uy Hoang, Bernardo Meza-Torres, Anna Forbes, Will Hinton, Sneha Anand, et al.

    Objective To evaluate Phenotype Execution and Modelling Architecture (PhEMA), to express sharable phenotypes using Clinical Query Language (CQL) and intensional SNOMED CT Fast Healthcare Interoperability Resources (FHIR) valuesets, for exemplar chronic disease, sociodemographic risk factor and surveillance phenotypes. Method We curated three phenotypes: Type 2 diabetes (T2DM), excessive alcohol use and incident influenza-like illness (ILI) using CQL to define clinical and administrative logic. We defined our phenotypes with valuesets, using SNOMED’s hierarchy and expression constraint language (ECL), and CQL, combining valuesets and adding temporal elements where needed. We compared the count of cases found using PhEMA with our existing approach using convenience datasets. Results The T2DM phenotype could be defined as two intensionally defined SNOMED valuesets and a CQL script. It increased the prevalence from 7.2% to 7.3%. Excess alcohol phenotype was defined by valuesets that added qualitative clinical terms to the quantitative conceptual definitions we currently use; this change increased prevalence by 58%, from 1.2% to 1.9%. We created an ILI valueset with SNOMED concepts, adding a temporal element using CQL to differentiate new episodes. This increased the weekly incidence in our convenience sample (weeks 26 to 38) from 0.95 cases to 1.11 cases per 100,000 people. Conclusions Phenotypes for surveillance and research can be described fully and comprehensibly using CQL and intensional FHIR valuesets. Our use case phenotypes identified a greater number of cases, whilst anticipated from excessive alcohol this was not for our other variable. This may have been due to our use of SNOMED CT hierarchy.


  • Open Access

    Hepatitis A Vaccination Coverage Among People With Chronic Liver Disease in England (HEALD): Protocol for a Retrospective Cohort Study

    by Bernardo Meza-Torres, Anna Forbes, William Elson, Debasish Kar, Gavin Jamie, William Hinton, Xuejuan Fan, Rachel Byford, Michael Feher, Martin Whyte, et al.

    Background: Hepatitis A outbreaks in the United Kingdom are uncommon. Most people develop mild to moderate symptoms that resolve, without sequelae, within months. However, in high-risk groups, including those with underlying chronic liver disease (CLD), hepatitis A infection can be severe, with a higher risk of mortality and morbidity. The Health Security Agency and the National Institute of Health and Care Excellence recommend preexposure hepatitis A vaccination given in 2 doses to people with CLD, regardless of its cause. There are currently no published reports of vaccination coverage for people with CLD in England or internationally. Objective: This study aims to describe hepatitis A vaccination coverage in adults with CLD in a UK primary care setting and compare liver disease etiology, sociodemographic characteristics, and comorbidities in people who are and are not exposed to the hepatitis A vaccine. Methods: We will conduct a retrospective cohort study with data from the Primary Care Sentinel Cohort of the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub database, which is nationally representative of the English population. We will include people aged 18 years and older who have been registered in general practices in the Research and Surveillance Centre network and have a record of CLD between January 1, 2012, and December 31, 2022, including those with alcohol-related liver disease, chronic hepatitis B, chronic hepatitis C, nonalcohol fatty liver disease, Wilson disease, hemochromatosis, and autoimmune hepatitis. We will carefully curate variables using the Systematized Nomenclature of Medicine Clinical Terms. We will report the sociodemographic characteristics of those who are vaccinated. These include age, gender, ethnicity, population density, region, socioeconomic status (measured using the index of multiple deprivation), obesity, alcohol consumption, and smoking. Hepatitis A vaccination coverage for 1 and 2 doses will be calculated using an estimate of the CLD population as the denominator. We will analyze the baseline characteristics using descriptive statistics, including measures of dispersion. Pairwise comparisons of case-mix characteristics, comorbidities, and complications will be reported according to vaccination status. A multistate survival model will be fitted to estimate the transition probabilities among four states: (1) diagnosed with CLD, (2) first dose of hepatitis A vaccination, (3) second dose of hepatitis A vaccination, and (4) death. This will identify any potential disparities in how people with CLD get vaccinated. Results: The Research and Surveillance Centre population comprises over 8 million people. The reported incidence of CLD is 20.7 cases per 100,000. International estimates of hepatitis A vaccine coverage vary between 10% and 50% in this group. Conclusions: This study will describe the uptake of the hepatitis A vaccine in people with CLD and report any disparities or differences in the characteristics of the vaccinated population. International Registered Report Identifier (IRRID): PRR1-10.2196/51861


  • Open Access

    Hepatitis A Vaccination Coverage Among People With Chronic Liver Disease in England (HEALD): Protocol for a Retrospective Cohort Study (Preprint)

    by Bernardo Meza-Torres, Anna Forbes, William Elson, Debasish Kar, Gavin Jamie, William Hinton, Xuejuan Fan, Rachel Byford, Michael Feher, Martin Whyte, et al.

    BACKGROUND Hepatitis A outbreaks in the United Kingdom are uncommon. Most people develop mild to moderate symptoms that resolve, without sequelae, within months. However, in high-risk groups, including those with underlying chronic liver disease (CLD), hepatitis A infection can be severe, with a higher risk of mortality and morbidity. The Health Security Agency and the National Institute of Health and Care Excellence recommend preexposure hepatitis A vaccination given in 2 doses to people with CLD, regardless of its cause. There are currently no published reports of vaccination coverage for people with CLD in England or internationally. OBJECTIVE This study aims to describe hepatitis A vaccination coverage in adults with CLD in a UK primary care setting and compare liver disease etiology, sociodemographic characteristics, and comorbidities in people who are and are not exposed to the hepatitis A vaccine. METHODS We will conduct a retrospective cohort study with data from the Primary Care Sentinel Cohort of the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub database, which is nationally representative of the English population. We will include people aged 18 years and older who have been registered in general practices in the Research and Surveillance Centre network and have a record of CLD between January 1, 2012, and December 31, 2022, including those with alcohol-related liver disease, chronic hepatitis B, chronic hepatitis C, nonalcohol fatty liver disease, Wilson disease, hemochromatosis, and autoimmune hepatitis. We will carefully curate variables using the Systematized Nomenclature of Medicine Clinical Terms. We will report the sociodemographic characteristics of those who are vaccinated. These include age, gender, ethnicity, population density, region, socioeconomic status (measured using the index of multiple deprivation), obesity, alcohol consumption, and smoking. Hepatitis A vaccination coverage for 1 and 2 doses will be calculated using an estimate of the CLD population as the denominator. We will analyze the baseline characteristics using descriptive statistics, including measures of dispersion. Pairwise comparisons of case-mix characteristics, comorbidities, and complications will be reported according to vaccination status. A multistate survival model will be fitted to estimate the transition probabilities among four states: (1) diagnosed with CLD, (2) first dose of hepatitis A vaccination, (3) second dose of hepatitis A vaccination, and (4) death. This will identify any potential disparities in how people with CLD get vaccinated. RESULTS The Research and Surveillance Centre population comprises over 8 million people. The reported incidence of CLD is 20.7 cases per 100,000. International estimates of hepatitis A vaccine coverage vary between 10% and 50% in this group. CONCLUSIONS This study will describe the uptake of the hepatitis A vaccine in people with CLD and report any disparities or differences in the characteristics of the vaccinated population. INTERNATIONAL REGISTERED REPORT PRR1-10.2196/51861